Hellas Liquidators File US$1.3 Billion Lawsuit against Leading Private Equity Funds

The Joint Compulsory Liquidators of Hellas Telecommunications (Luxembourg) II SCA, Andrew Hosking and Simon Bonney, after consultation with legal advisors and the company’s creditors’ committee, have filed a lawsuit against TPG Capital Management, L.P. and Apax Partners LLP, among other defendants, seeking damages of more than US$1.3 billion plus interest. The complaint filed in the United States Bankruptcy Court for the Southern District of New York alleges that TPG and Apax engaged in wrongdoing giving rise to claims of actual and constructive fraudulent conveyance and unjust enrichment.

More >>

Clifford Chance advises Hopu Investment Management as part of a US$2.5 billion investment in Global Logistic Properties

Leading international law firm Clifford Chance has recently advised Hopu Investment Management, as part of a consortium, on a combined investment of up to US$2.5 billion in Global Logistic Properties (GLP), a Singapore-listed provider of logistics facilities in China, Japan and Brazil. GLP intends to use the majority of the proceeds to enhance access to strategic land holdings and customers, and further develop its network in China. This transaction is subject to regulatory and GLP shareholder approval.

More >>

Tags:  Clifford Chance LLP

Davis Polk Advises Temasek on Its Investment in TutorGroup Holding

Davis Polk advised Temasek in connection with its affiliate’s investment in Series B preferred shares of TutorGroup Holding. Affiliates of Alibaba Group, the China-based e-commerce company, and Qiming Venture Partners, a China-based venture capital fund, also participated in this round of financing. The aggregate investment size for this Series B round was close to $100 million. More >>

Tags:  Davis Polk & Wardwell LLP

Shearman & Sterling Represents Underwriters in Connection with HSBC Holdings plc’s US$3.5 Billion Notes Offering

Shearman & Sterling represented the underwriters (led by HSBC Securities (USA) Inc.) in connection with HSBC Holdings plc’s offering of US$2 billion aggregate principal amount of 4.250% subordinated notes due 2024 and US$1.5 billion aggregate principal amount of 5.250% subordinated notes due 2044. The subordinated notes qualify as Tier 2 capital under Basel III and are subject to the exercise of “bail-in” powers by UK regulatory authorities.

More >>

Tags:  Shearman & Sterling LLP

Mayer Brown successfully defends $22.8 billion contract award to Consolidated Nuclear Security

Mayer Brown’s Government Contracts group successfully represented Consolidated Nuclear Security LLC (CNS) in securing the award of a $22.8 billion contract by the National Nuclear Security Administration (NNSA) in the face of three protests by a competitor. The contract is believed to be the largest ever awarded by the US Department of Energy and the NNSA.

More >>

Tags:  Mayer Brown LLP

Simpson Thacher Represents JLL Partners and Patheon in $2 Billion Financing for Combination of Patheon and the Pharmaceutical Products Business of Royal DSM

The Firm represented JLL Partners, Inc. and its 56%-owned portfolio company, Patheon Inc., in the financing transactions for JLL Partners’ take-private acquisition of Patheon and Patheon’s related combination with the Pharmaceutical Products business of Koninklijke DSM N.V., known as Royal DSM. As a result of the transactions, which closed on March 11, 2014, the combined business is held by JLL/Delta Dutch Newco B.V. (the “Company”), which is 51% owned by JLL Partners and 49% owned by Royal DSM.

More >>

Tags:  Simpson Thacher & Bartlett LLP

Firm Advises on Synageva Biopharma’s $211.5 Million Equity Offering

On March 5, Synageva BioPharma Corp. announced the pricing of its previously announced underwritten public offering of common stock consisting of 2 million shares at $105.75 per share. Willkie represented book-running managers Goldman, Sachs & Co., J.P. Morgan Securities LLC, and Morgan Stanley & Co. LLC, in the offering. In connection with this offering, Synageva granted to the underwriters a 30-day option to purchase 300,000 additional shares of common stock. Massachusetts-based Synageva is a clinical stage biopharmaceutical company developing therapeutic products for life-threatening rare diseases. Willkie previously advised on Synageva’s $113 million and $90 million stock offerings in 2013 and 2012, respectively.

More >>